|
Cardiokinase™ |
NSK-SD™ |
Other Brands |
Exclusively Developed by Dr. Sumi |
|
|
|
Improves Circulation |
|
|
Not Known |
Moderate Fibrinolytic Activity |
|
|
Not Known |
High Fibrinolytic Activity |
20% more Fibrin Units (FU) per capsule than NSK-SD; Exceeds all current standards |
|
Not Known |
Lowers Whole Blood Viscosity |
|
|
Not Known |
High Bioavailability |
10% better lymphatic absorption than NSK-SD |
|
|
Standardized for Potency |
|
|
|
Derived from Powerful Novel “N” Strain |
|
|
|
Composition Patent |
|
|
|
Clinical Trials |
|
|
|
Hypoallergenic |
|
|
|
Important Notes:
Other Brands in this comparison chart are considered to be any proteolytic enzyme (bromelain, papain, fungal enzymes). These brands are based upon a false identification of FUs activity and are not nattokinase. (See note below from Dr. Holsworth explaining this in detail)
Since my introduction of nattokinase as a safe and effective therapeutic modality into the clinical and hospital setting in 2002, I have been searching for a standardization of nattokinase that will allow health professionals to determine two important facts concerning the use of nattokinase;
1. Biochemical validation that the substance is nattokinase, specificity
2. Accurate determination of fibrinolytic activity in vitro, sensitivity
The previous standardization of nattokinase identified activity in fibrinolytic degradation units (FUs). Unfortunately, the test does not validate whether the enzyme is in fact, nattokinase. Any proteolytic enzyme (bromelain, papain, fungal enzymes) tested using this test would erroneously report fibrinolytic activity or the ability to degrade cross-linked fibrin. Many companies manufactured, produced and falsely identified their bulk and/or finished retail products as “nattokinase” based upon a false identification of FUs activity. Can you imagine a physician prescribing insulin that was not truly insulin or the units of the insulin were incorrect? Many patients’ lives depend upon securing a valid form of nattokinase and accurate determination of its activity because they do not have a pharmaceutical drug such as an anti-coagulant that they can tolerate and/or is effective in the prevention of their condition of inadvertent blood formation.
In addition, the substrate utilized in the previously standardization for determining the activity was not soluble so activity determinations were inaccurate and not reproducible.
Dr. Hiroyuki Sumi, Ph.D., a medical researcher in thrombolytics who discovered nattokinase in the 1980's, has developed and published a new standardization method that validates not only the biochemical identification of the enzyme as nattokinase but also the activity or ability of nattokinase to degrade or lyse cross-linked fibrin in International Units. Now, physicians and patients are insured that they are receiving authentic nattokinase in a stable and quantified amount of activity to address various medical indications.
-Dr. Ralph Holsworth
Nattokinase Pioneer & Researcher
|